
Conference Coverage
about 14 hours ago
APOL1 Genotypes and Kidney Failure Risk: Bessie A. Young, MD, MPHabout 15 hours ago
Semaglutide in Type 2 Diabetes and CKD: Katherine R. Tuttle, MD, FASNabout 17 hours ago
AMCP Nexus 2026 to Address Key Shifts in Managed Care Pharmacyabout 19 hours ago
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPHabout 19 hours ago
Colonization vs Infection: Rethinking C. Diff PreventionLatest Content

AMCP Nexus 2026 to Address Key Shifts in Managed Care Pharmacy

One-Size Dialysis Volume Goals Fall Short in CKD: Jennifer Flythe, MD

Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36

Dialysis Access, Church CKD Screening Address Kidney Care Inequities

Expert Panel Updates Consensus on Mantle Cell Lymphoma Care Using Pan-Asian Data

Shorts










Center on Health Equity & Access
All News

At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.

At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.

Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.

About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.

A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.

Nearly 72% of patients hospitalized for heart failure had 2 or more other CKM conditions, with the strongest links to poor outcomes in HFrEF.






























